NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis → Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad) Free VNDA Stock Alerts $6.50 +0.58 (+9.80%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$6.20▼$6.7550-Day Range$4.05▼$6.5052-Week Range$3.30▼$6.76Volume4.26 million shsAverage Volume1.25 million shsMarket Capitalization$378.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Vanda Pharmaceuticals alerts: Email Address Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.55Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 starsMedical Sector677th out of 917 stocksPharmaceutical Preparations Industry319th out of 431 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals.Read more about Vanda Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.52% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 11.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 2.0 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vanda Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -81.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -81.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesJune 13 at 9:00 PM | globenewswire.comGlobal Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%June 13 at 10:02 AM | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakJune 13 at 8:36 AM | reuters.comFuture Pak raises cash portion of buyout offer for VandaJune 10, 2024 | businesswire.comCIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and NeuromodulationJune 10, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.June 6, 2024 | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.May 30, 2024 | prnewswire.comVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceMay 30, 2024 | prnewswire.comVanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®May 29, 2024 | prnewswire.comVanda Pharmaceuticals Announces Presentations at SLEEP 2024May 24, 2024 | marketwatch.comVanda Pharma Rejects Future Pak's Sweetened Takeover BidMay 24, 2024 | msn.comVanda Pharmaceuticals rejected sweetened bid from Future PakMay 24, 2024 | prnewswire.comVanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersMay 15, 2024 | markets.businessinsider.comVanda Pharma Reports Positive Results From Second Phase III Study Of TradipitantMay 15, 2024 | msn.comVanda reports positive Phase 3 data for motion sickness drugMay 15, 2024 | prnewswire.comVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessMay 10, 2024 | finance.yahoo.comVanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue EstimatesMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Vanda Pharmaceuticals Inc Earnings CallMay 8, 2024 | msn.comVanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46MMay 8, 2024 | markets.businessinsider.comVNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comVanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakMay 7, 2024 | markets.businessinsider.comVanda Pharma Receives Revised Unsolicited Takeover Proposal From Future PakSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/14/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees203Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.51 million Net Margins-2.75% Pretax Margin-2.17% Return on Equity-0.90% Return on Assets-0.76% Debt Debt-to-Equity RatioN/A Current Ratio4.71 Quick Ratio4.69 Sales & Book Value Annual Sales$192.64 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$9.47 per share Price / Book0.69Miscellaneous Outstanding Shares58,200,000Free Float53,717,000Market Cap$378.30 million OptionableOptionable Beta0.71 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 64)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Timothy Williams (Age 48)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 58)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Scott L. HowellChief People OfficerKey CompetitorsAkouosNASDAQ:AKUSGossamer BioNASDAQ:GOSSAnaptysBioNASDAQ:ANABVBI VaccinesNASDAQ:VBIVAlbireo PharmaNASDAQ:ALBOView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 46,969 shares on 5/20/2024Ownership: 0.081%Jacobs Levy Equity Management Inc.Sold 10,290 shares on 5/16/2024Ownership: 2.439%Public Employees Retirement System of OhioSold 5,046 shares on 5/15/2024Ownership: 0.201%Price T Rowe Associates Inc. MDBought 2,425 shares on 5/15/2024Ownership: 0.027%Vanguard Group Inc.Sold 60,504 shares on 5/10/2024Ownership: 5.835%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed in 2024? Vanda Pharmaceuticals' stock was trading at $4.22 at the beginning of 2024. Since then, VNDA shares have increased by 54.0% and is now trading at $6.50. View the best growth stocks for 2024 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by $0.12. The biopharmaceutical company had revenue of $47.46 million for the quarter, compared to analyst estimates of $48.50 million. Vanda Pharmaceuticals had a negative net margin of 2.75% and a negative trailing twelve-month return on equity of 0.90%. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.83%), Acadian Asset Management LLC (4.07%), Jacobs Levy Equity Management Inc. (2.44%), Assenagon Asset Management S.A. (1.27%), Sei Investments Co. (0.89%) and GSA Capital Partners LLP (0.84%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VNDA) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredMy 3 Top CryptocurrenciesMore than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.